The advent of single-cell omics technologies has revolutionized our understanding of the complex cellular landscape in cancer. Traditional bulk sequencing ...

A new study published in The Journal of Immunology by researchers at the Josep Carreras Leukaemia Research Institute (IJC) ...

Cancer immunology is advancing rapidly as researchers seek to unravel the complex, dynamic relationships between tumor cells, immune populations, and the ...

The 4,000-year-old drug, most commonly used to treat pain, prevents certain tumours from forming and spreading across the ...

Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars, treating osteoporosis and cancer-related bone ...

Biocon Ltd has received approval from Health Canada for its biosimilars, Bosaya and Vevzuo, intended for treating osteoporosis and cancer-related bone complications. This approval underscores Biocon's ...

Biocon added 1.66% to Rs 364.45 after the company said that Health Canada has granted a notice of compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vezuo (denosumab), a biosimilar ...

While modern life includes many conveniences, humans are still incessantly exposed to a variety of metabolic stresses we have ...

Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya (denosumab), a biosimilar to Prolia, and Vezuo (denosumab), a biosimilar to Xgeva, on 03 April 2026. Both ...

Bengaluru/Toronto: Biocon is stepping up its global biosimilars play with fresh approvals in Canada, targeting large patient ...

We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Immutep Limited is among the oversold stocks to invest in now. TheFly reported on April 15 that IMMP announced that the U ...

ABBV's oncology unit faces declining Imbruvica sales and pricing pressure, likely dragging Q1 revenues despite growth from newer cancer therapies.